Segulah Medical Acceleration announces investment in Senzime
Segulah Medical Acceleraion AB (“SMA”) has made a commitment regarding an investment in Senzime AB (publ) (“Senzime” or “the Company”). As previously communicated in a press release from the Company, Senzime’s board of directors has resolved on a directed share issue of SEK 117 million, led by SMA together with Carnegie Fonder and existing shareholders Fjärde AP-fonden, Crafoordska Stiftelsen, Handelsbanken Fonder, Fredrik Rapp, and Swedbank Robur.
Senzime is a Swedish medical device company that develops and markets patient monitoring systems. Medical procedures, particularly those involving anesthesia, encompass dynamic and intricate physiological responses that need to be accurately monitored. The increasing utilization of neuromuscular blocking agents in anesthesia has been a game-changer in surgery and are now used in approximately 50 % of all surgeries. However, traditional, non-quantitative methods to monitor neuromuscular blockade have been associated with an increased risk for complications. Senzime’s TetraGraph system enables quantitative monitoring of neuromuscular blockade, and is designed for real-time observation of neuromuscular function during and post-surgery, aiming to prevent anesthesia related complications. The TetraGraph system offers a new gold standard in neuromuscular monitoring, in line with new clinical guidelines in both US and Europe.
“SMA has followed Senzime for quite some time and we’re now convinced that the company has started an exciting growth story and will therefore invest SEK 50 million. Senzime has managed to standout in the competitive US market by recently securing several large top-tier US accounts including hospital systems, university hospitals and several large hospitals, accounts with the potential to generate significant recurring revenues each year. Securing large top-tier accounts underscores the global applicability and excellence of Senzime’s patient monitoring solutions, which SMA is excited to be a part of going forward.”, comments Maria Tell, Investment Director at Segulah Medical Acceleration.
Senzime’s share issue is directed to a limited number of new and existing investors, including the new shareholders SMA and Carnegie Fonder. Existing shareholders participating in the issue are Fredrik Rapp, Fjärde AP-fonden, Crafoordska Stiftelsen, Handelsbanken Fonder, and Swedbank Robur, all of whom have expressed a long-term commitment to the Company. The issue consists of a total of 18,000,000 shares at a subscription price of SEK 6.50 per share, corresponding to a premium of 1.5 % compared to the average price of the last 20 days (VWAP). Through the share issue, Senzime will receive a total of SEK 117 million (before transaction costs).
“We are now closing another successful directed issue and welcome additional long-term institutional investors. The market interest has been significant, and Senzime is now well-capitalized and has the right fundamentals to realize the strategic and financial plan” comments Philip Siberg, CEO at Senzime in a press release from the Company.
The proceeds from the issue will primarily be used to continue strengthening the Company’s commercial expansion related to the recently published European and American guidelines, ensure delivery in innovation projects, and finance the Company’s general working capital needs in light of expected growth.
The issue is conditional upon approval by a general meeting, which is scheduled for October 19 2023. Shareholders representing a total of approximately 55 % of the shares and votes in the Company have declared that they will vote in accordance with the proposal at the meeting. Subscription commitments have been made for SEK 99,775,000 of the issue volume and declarations of intent for the remaining SEK 17,225,000.
About Senzime AB (publ)
Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.
Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at www.senzime.com.
About Segulah Medical Acceleration AB
Segulah Medical Acceleration (“SMA”) is a Scandinavia-based investment company focusing on innovative medical technology companies with global potential. SMA’s objective is to be an active partner and help its portfolio companies accelerate growth and internationalization and reach commercial proof of concept. SMA’s geographic investment remit is focused on Scandinavia and other Western European countries. The areas within Medtech that SMA prioritizes include medical devices and consumables, diagnostics, life science tools, and digital technologies. www.segulahmedical.com
Please contact Maria Tell, Investment Director at SMA, with any questions. email@example.com
Segulah Medical Acceleration announces investment in Senzime2023.09.28
Segulah Medical Acceleraion AB (“SMA”) has made a commitment regarding an investment in Senzime AB (publ) (“Senzime” or “the Company”). As previously communicated in a press release from the Company, Senzime’s board of directors has resolved on a directed share issue of SEK 117 million, led by SMA together with Carnegie Fonder and existing shareholders Fjärde AP-fonden, Crafoordska Stiftelsen, Handelsbanken Fonder, Fredrik Rapp, and Swedbank Robur.Read more
Collective Minds Radiology announces closing of SEK 84m financing, led by Segulah Medical Acceleration and existing shareholders2023.08.28
Collective Minds Radiology, a fast-growing, Swedish health-tech company with a mission to build the world’s largest platform and community for healthcare collaboration, announces the closing of a SEK 84 million funding round. The round was led by Segulah Medical Acceleration (“SMA”), a Scandinavia-based life science-focused investment company, together with existing shareholders, Brightly Ventures, Tradecity, Crista Galli Ventures, and several European business angels. The funding will enable Collective Minds to accelerate the commercial expansion of its professional healthcare collaboration platform for clinical consultation, education, and clinical research, with the aim of increasing the quality of care.Read more
Navinci appoints Eva Pisa as chairman, further strengthens the leadership team and establishes a Scientific Advisory Board2023.02.20
In line with the company’s vision of becoming a leader in spatial proteomics, Navinci further strengthens its organization and is pleased to announce the appointment of Dr. Eva Pisa as new chairman of the board, Dr. Caroline Gallant as new CTO and the formation of a Scientific Advisory Board chaired by Professor Ulf Landegren.Read more
Allurion to Go Public on NYSE2023.02.16
SMA portfolio company Allurion Technologies, a global leader in weight loss technology, to become publicly listed through business combinationRead more
Segulah Medical Acceleration Announces Investment in Allurion Technologies2022.09.13
Segulah Medical Acceleration AB (“SMA”) has made a minority investment in US-based Allurion Technologies during their July 2021 extension of the $34m Series D financing. The Series D round was led by Novalis LifeSciences and Romulus Capital.Read more
Segulah Medical Acceleration Announces Investment in Navinci Diagnostics2022.07.12
Navinci Diagnostics AB, a Swedish life science company developing innovative tools for spatial proteomics research, announces the closing of SEK 90 million financing. The round was led by Segulah Medical Acceleration (”SMA”), a Scandinavia-based life science-focused investment company, together with existing shareholders, including Landegren Gene Technology AB, Nexttobe AB, and Beijer Ventures AB.Read more
Signifier Medical Technologies is granted HCPCS Codes2022.02.28
Signifier Medical Technologies is granted HCPCS Codes for eXciteOSA to help patients access innovative technologyRead more
Segulah Medical Acceleration Announces Investment in Signifier Medical Technologies2021.07.30
Segulah Medical Acceleration AB (SMA) announced today that it has invested in UK-based Signifier Medical Technologies’ USD 35 million Series D convertible financing. The financing was jointly led by SMA together with Angelus Venture Fund I L.P., Alan Howard (co-founder of Brevan Howard Asset Management) and Pioneer Healthcare Partners LP.Read more
Segulah Medical Acceleration Announces Investment in SAGA Diagnostics2021.06.30
Segulah Medical Acceleration AB (SMA) announced today that it has invested in cancer liquid biopsy and genomic testing company SAGA Diagnostics’ oversubscribed SEK 106 million (€10.5 million) Series A2 equity financing round. The round was led by SMA together with the Sciety investment syndicate with strong support from existing shareholders such as Hadean Ventures.Read more
Segulah Medical Acceleration Announces Investment in Quanta Dialysis Technologies2021.06.28
Segulah Medical Acceleration AB (SMA) a specialized growth equity investment firm focused on Medtech and related areas, announced today that it has invested in Quanta Dialysis Technologies oversubscribed and upsized $245 million Series D equity financing round. This financing is the largest ever private funding round for a dialysis device company.Read more
Blue chip investors back new MedTech investment company2021.04.29
Segulah Medical Acceleration, SMA, is a newly formed company specializing in medical technology investments, with a focus on Sweden, Scandinavia and Western Europe. The company is financed by leading institutions and prominent private investors, whose initial commitments amount to approximately SEK 1.2 billion.Read more